The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation - PubMed
5 hours ago
- #Neurological diseases
- #NAD augmentation
- #Pharmacokinetics
- NAD augmentation therapy (NAD-AT) is being explored for neurological diseases, but its human pharmacokinetic profile is not fully understood.
- A phase I trial studied oral NAD precursors in healthy individuals and Parkinson's disease patients, showing blood NAD levels plateau after two weeks and decline slowly post-treatment.
- Cerebral NAD levels increased after four weeks of treatment, with NAD-related metabolites showing faster dynamics than NAD itself.
- Effective NAD-AT requires sustained oral administration for 2-4 weeks, with once-daily dosing sufficient to maintain stable NAD levels.
- NAD responses varied among individuals but were not affected by disease status or sex, indicating broad applicability.
- Researchers involved have patents related to nicotinamide riboside for treating Parkinson’s disease.